Search
Menu

Goal and Learning Outcomes

The goal of this continuing education module is to provide interprofessional team members with evidence-based guidance on the assessment and management of pain in a way that balances concerns for pain reduction, functional improvement, and avoidance of treatment-related harms.
  • Describe the need to balance concerns about potential harms that result from uncontrolled pain and iatrogenic harms from its treatment
  • Select and properly use evidence-based pain assessment tools based on the patient’s age and ability to communicate
  • Create and implement a pain treatment plan that integrates guided imagery with pharmacological and non-pharmacological therapies based on evidence-based guidelines given the pain type and patient specific risk factors or comorbidities
  • Evaluate multimodal treatment plans with interprofessional input for patients with complex or persistent pain

Course Authors

Accreditation Information

NURSES

In support of improving patient care, Relias LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Provider approved by the California Board of Registered Nursing, CEP#13791

 

CEBroker

Relias LLC reports to CEBroker for the following boards (Provider # 50-1489): Arkansas State Board Of Nursing, District Of Columbia Board Of Nursing, Florida Board Of Nursing, Georgia Board Of Nursing, New Mexico Board Of Nursing, South Carolina Board Of Nursing and  West Virginia Board Of Examiners For Registered Professional Nurses

 

Please check the licenses/certifications section under my account (after logging in) to make sure you have entered a valid license number. This information is required for correct reporting of your course completions to CE Broker.

 

Disclosures

None of the planners/faculty, unless otherwise noted, for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.